Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104675 · ClinicalTrials.gov registry record · Phase 2
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Peritoneal Cancer, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT01104675: Completed Phase 2 study of Ovarian Cancer and Peritoneal Cancer, sponsored by CASI pharmaceuticals.
NCT01104675 is a Phase 2 study of Ovarian Cancer and Peritoneal Cancer that has completed, run by CASI pharmaceuticals. The registered enrollment target is 64 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01104675, a Phase 2 study of Ovarian Cancer and Peritoneal Cancer, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Conditions Studied
Interventions
- DRUG ENMD-2076
Study Locations (6)
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Massachusetts
- Dana Farber/Partners Cancer Care - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01104675 record still lists
NCT01104675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which ENMD-2076 is the first listed.
NCT01104675 lists 6 locations in 6 states (Colorado, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT01104675 about?
NCT01104675 is a clinical study titled "Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer". The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
What is the current status of trial NCT01104675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-04. Estimated completion is 2012-12.
What conditions does trial NCT01104675 study?
This clinical trial studies the following conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Cancer.
What interventions are being tested in trial NCT01104675?
The interventions under investigation include: ENMD-2076 (DRUG).
Who is sponsoring clinical trial NCT01104675?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01104675 being conducted?
This trial has 6 study locations across Colorado, Illinois, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01104675's enrollment target sits among peer trials
64 188th of 322 higher than 135 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia